1.Endogenous basic fibroblst growth factor is a protective factor against myocardial ischemia/reperfusion injury of rats
Zhisheng JIANG ; Xiaohong WANG ; Shulian LI ; Chaoshu TANG
Chinese Journal of Pathophysiology 1989;0(06):-
AIM: To observe the role of exogenous and endogenous basic fibroblst growth factor (bFGF) on myocardial ischemia/reperfusion(I/R) injury of rats.METHODS:bFGF and bFGF antiserum were applied to rat isolated I/R heart. Myocardial function, coronary effluent volume,protein and myoglobin content as well as LDH activity in coronary effluent fluid, myocardial calcium, MDA and ATP concentration as well as PKC, MAPK activity were measured. RESULTS:Compared with control, myocardial function in I/R group significantly decreased. Protein, myoglobin content and LDH activity in coronary effluent liquid as well as myocardial MDA and calcium content increased, while myocardial ATP concentration decreased(all P
2.Prognostic analysis of brain metastases from primary breast cancer treated with stereotactic radiotherapy
Xiujun CHEN ; Jianping XIAO ; Xiangpan LI ; Xuesong JIANG ; Ye ZHANG ; Yingjie XU ; Shulian WANG ; Yexiong LI
Chinese Journal of Radiation Oncology 2012;(6):496-499
Objective To explore the prognostic factors of brain metastases from primary breast cancer treated with stereotactic radiotherapy (SRT).Methods Retrospectively analyze 37 brain metastatic patients from primary breast cancer.Among these patients nineteen were treated with stereotactic radiotherapy alone,eight patients were treated with whole brain radiotherapy (WBRT) plus SRT,the other ten patients were intracranial recurrence after WBRT and treated with SRT for salvage.Kaplan-Meier analyses were used to calculate survival time.Logrank and Cox proportional hazards regression analyses were performed for univariate and multivariate analyses.Results The median follow-up time were 11 months and 15 months for the whole group and the alive.The median overall survival time was 11 months (95% CI =6-16.month) for the whole group.The median overall survival time was 13.5 months for the whole group.In univariate analysis,the triple negative breast cancer (x2 =5.95,P =0.004),lower Karnofsky performance score (KPS,x2 =13.85,P =0.000),the interval between the diagnosis of the primary tumor and brain metastases ≤ 30 months (x2 =6.62,P =0.010),high RPA grade (x2 =15.35,P =0.000) and intracranial recurrence after whole brain radiotherapy (x2 =4.43,P =0.035) were negative prognostic factors for brain metastasis of breast cancer treated with stereotactic radiotherapy.In multivariate analyses,the triple negative breast cancer (x2 =9.58,P =0.008),lower KPS (x2 =6.65,P =0.010),and intracranial recurrence after whole brain radiotherapy (x2 =3.95,P =0.047) were negative prognostic factor.Conclusion The triple negative breast cancer,lower KPS,and intracranial recurrence after WBRT were negative prognostic factor for brain metastasis from primary breast cancer treated with SRT.
3.Comparison of static intensity-modulated radiation therapy and volumetric modulated arc therapy in early-stage primary mediastinal B-cell lymphoma
Liming XU ; Minglei KANG ; Bo JIANG ; Hui FANG ; Jing JIN ; Weihu WANG ; Shulian WANG ; Yueping LIU ; Yongwen SONG ; Qingfeng LIU ; Qingxin WANG ; Jianrong DAI ; Yexiong LI
Chinese Journal of Radiation Oncology 2015;(6):638-643
Objective To compare target dosimetric distribution and normal tissue radiation between different static intensity?modulated radiation therapy ( IMRT) plans and volumetric modulated arc therapy ( VMAT) and to identify the best IMRT plan for patients with primary mediastinal B?cell lymphoma ( PMBCL) . Methods A total of 16 patients ( 8 males and 8 females) with early?stage ( Ann?Arbor stageⅠ) PMBCL were enrolled in this study,with doses of 45 Gy for primary gross tumor volume ( PGTV) and 40 Gy for planning target volume (PTV).Four plans were designed for each patient,consisting of static IMRT (5F?IMRT,7F?IMRT,9F?IMRT) and VMAT,and the target dosimetric distribution,normal tissue radiation dose,and efficiency of each plan were evaluated. The difference of dose was analyzed by analysis of variance. Results The mean conformity index ( CI) and homogeneity index ( HI) for PGTV in 5F?,7F?,9F?IMRT and VMAT were 1. 01 and 1. 10, 1. 01 and 1. 10, 1. 01 and 1. 10, and 1. 01 and 1. 11 ( P= 0. 963 and 0. 843) ,respectively,while these two indices for PTV were 1. 04 and 1. 22,1. 03 and 1. 19,1. 03 and 1. 17, and 1. 08 and 1. 14( P=0. 964 and 0. 969) ,respectively. The parameters of volume and dose were similar on normal tissue ( P= 0. 192?1. 000 ) . The treatment time and number of monitor units in 9F?IMRT were significantly higher than those in other static IMRT plans and VMAT ( P=0. 000,0. 000) ,and among these plans,VMAT had the lowest number of monitor units ( 13 345. 0 MU) and the shortest treatment time ( 5. 9 min) . Conclusions The target volume coverage of 7F?and 9F?IMRT is better than that of 5F?IMRT and VMAT.For early?stage PMBCL,VMAT is not superior to IMRT in terms of dosimetry,especially with a larger area of low?dose radiation to the breast,but it is highly efficient in practice.
4. Effects of preexisting donor-specific HLA antibodies for graft failure in un-manipulated haploidentical hematopoietic stem cell transplantation
Rongli ZHANG ; Xiaohui ZHENG ; Lukun ZHOU ; Ying ZHANG ; Shulian CHEN ; Donglin YANG ; Erlie JIANG ; Jialin WEI ; Yong HUANG ; Qiaoling MA ; Weihua ZHAI ; Sizhou FENG ; Mingzhe HAN ; Yi HE
Chinese Journal of Hematology 2018;39(3):190-195
Objective:
To investigate the effects of donor-specific HLA antibodies(DSA) for graft failure in un-manipulated haploidentical hematopoietic stem cell transplantation(haplo-HSCT) and the feasible treatment for DSA.
Methods:
HLA antibodies were examined using the Luminex-based single Ag assay for 92 patients who were going on haplo-SCT and the correlations of graft failure and DSA among the patients who had finished SCT were analyzed.
Results:
Of the total 92 patients who were going on haplo-HSCT, sixteen (17.4%) patients were HLA Ab-positive, including six (6.5%) patients with antibodies corresponding to donor HLA Ags (DSA-positive). Among the patients who had finished the haplo-HSCT with conventional myeloablative conditioning regimen, the engraftment rate was significantly higher in DSA (-) patients than that in DSA (+) patients [92.3% (24/26)
5.Pattern of nodal recurrence after curative resection in Siewert Ⅱ and Ⅲ locally advanced adenocarcinoma of gastroesophageal junction
Jiajia ZHANG ; Zhenwei LIANG ; Ying LI ; Xin WANG ; Yuan TANG ; Tongtong LIU ; Yanru FENG ; Ning LI ; Jing YU ; Shuai LI ; Hua REN ; Shuangmei ZOU ; Jun JIANG ; Wei HAN ; Weihu WANG ; Shulian WANG ; Yongwen SONG ; Yueping LIU ; Hui FANG ; Xinfan LIU ; Zihao YU ; Yexiong LI ; Liming JIANG ; Jing JIN
Chinese Journal of Radiation Oncology 2016;25(4):356-361
Objective To investigate the pattern of nodal recurrence after curative resection in adenocarcinoma of the gastroesophageal junction ( AGE ) , and to provide a basis for delineation of the radiation range in the high-risk lymphatic drainage area.Methods A retrospective analysis was performed in 78 patients with locally advanced AGE who were newly treated in our hospital from January 2009 to December 2013 and had complete clinical data.All patients received curative resection and were pathologically diagnosed with stage T3/T4 or N (+) AGE.Those patients were also diagnosed with SiewertⅡor Ⅲ AGE by endoscopy, upper gastroenterography, macroscopic examination during operation, and pathological specimens.None of the patients received preoperative or postoperative radiotherapy.All patients were diagnosed by imaging with postoperative nodal recurrence.The computed tomography images of those
patients were accessible and had all the recurrence sites clearly and fully displayed.Results The median time to recurrence was 10 months ( 1-48 months) , and 90%of the recurrence occurred within 2 years after surgery.The lymph nodes with the highest risk of recurrence were No.16b1( 39%) , No.16a2( 37%) , No.9 (30%), and No.11p (26%), respectively.There was no significant difference in the recurrence rate within each lymphatic drainage area between patients with SiewertⅡandⅢAGE ( P=0.090-1.000) .The lymph nodes with the most frequent recurrence were No.16b1, No.16a2, No.9, No.16b2, No.11p, and No.7 in patients with stage N3 AGE and No.11p, No.16b1, No.16a2, No.9, No.8, and No.7 in patients with stage non-N3 AGE.Patients with stage N3 AGE had a significantly higher recurrence rate in the para-aortic regions (No.16a2-b2) than those with stage non-N3 AGE (67%vs.33%, P=0.004, OR=4.00, 95% CI=1.54-10.37) .Conclusions The lymph nodes with the highest risk of recurrence are located in the celiac artery, proximal splenic artery, and retroperitoneal areas ( No.16a2 and No.16b1) in patients with SiewertⅡorⅢlocally advanced AEG.Moreover, patients with stage N3 AGE have a higher risk of retroperitoneal recurrence.The above areas should be involved in target volume delineation for postoperative radiotherapy.
6.Correlation analysis between MRI parameters and prognosis in locally advanced rectal cancer patients receiving chemoradiotherapy
Silin CHEN ; Shuai LI ; Ning LI ; Wenyang LIU ; Liming JIANG ; Jun JIANG ; Hua REN ; Shulian WANG ; Yongwen SONG ; Yueping LIU ; Hui FANG ; Ningning LU ; Yu TANG ; Shunan QI ; Bo CHEN ; Junqin LEI ; Jinming SHI ; Yexiong LI ; Jing JIN ; Yuan TANG
Chinese Journal of Radiation Oncology 2020;29(7):529-534
Objective:To investigate the relationship between MRI parameters and clinical prognosis before and after chemoradiotherapy in patients with locally advanced rectal cancer.Methods:Clinical and follow-up data of 96 patients with locally advanced rectal cancer who were initially treated in the Cancer Hospital of Chinese Academy of Medical Sciences from 2015 to 2017 were retrospectively analyzed. All patients received preoperative chemoradiotherapy, followed by delayed radical surgery at 6-13 weeks after radiotherapy. MRI assessment was performed twice around radiotherapy which were within 4 weeks before the treatment and 4-8 weeks after it. Correlation analysis was utilized to determine the association between MRI assessment and 3-year disease-free survival (DFS).Results:Of the all patients, 80 (83%) had T 3 stage, 16(17%) had T 4 stage, 14 (15%) had N 0 stage, and 82 (86%) had N 1-2 stage. Among them, 69(72%) and 58(60%) patients were positive for MRF and EMVI. The median dose of radiotherapy was 50 Gy, and all patients were sensitized by simultaneous capecitabine. After chemoradiotherapy, T-downstage rate of the whole group was 24%, and 50% for the N-downstage rate. The MRF-and EMVI-positive rates were significantly decreased to 37% and 27% after chemoradiotherapy (both P<0.001). Univariate and multivariate analyses showed that N staging and EMVI status change were significantly correlated with the 3-year DFS. Conclusion:MRI after concurrent chemoradiotherapy reveals that positive EMVI throughout the treatment and N 1-N 2 staing are poor prognostic factors of DFS, suggesting the need for improving the treatment.
7.Comparison of the value of two scores for predicting prognosis in patients with locally advanced rectal cancer undergoing concurrent chemoradiotherapy plus surgery
Silin CHEN ; Yuan TANG ; Ning LI ; Liming JIANG ; Jun JIANG ; Shulian WANG ; Yongwen SONG ; Yueping LIU ; Hui FANG ; Ningning LU ; Shunan QI ; Bo CHEN ; Yexiong LI ; Jing JIN
Chinese Journal of Radiation Oncology 2021;30(6):563-568
Objective:To evaluate the prognostic significance of neoadjuvant rectal (NAR) score and downstaging depth score (DDS) after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC).Methods:Retrospective analysis was performed for 200 patients with LARC (T 3-T 4 and/or N 1-N 2, M 0), who were initially treated in the Cancer Hospital of Chinese Academy of Medical Sciences from 2015 to 2018. All patients had baseline MRI data and received preoperative nCRT and radical resection. All patients received preoperative radiotherapy with a dose of 45-50Gy combined with concurrent capecitabine. The effect of NAR and DDS scores on clinical prognosis was statistically compared. The 3-year disease-free survival (DFS) was calculated using the Kaplan- Meier method and compared by the log- rank test. Cox proportional hazards model was used to perform multivariate survival analysis. The predictive performance for 3-year DFS was calculated using the receiver operating characteristic (ROC) curve. Results:The median follow-up time was 30.5(10.6-54.0) months. In terms of DDS, the 3-year DFS rate was 56.4% in the DDS ≤0 group, significantly lower than 83.0% in the DDS >0 group ( P=0.002). In terms of NAR score, the 3-year DFS rates were 90.1%, 73.8% and 53.6% in NAR score ≤8, 8-16 and>16 groups, respectively ( P<0.001). In the whole cohort, the area under the ROC curve (AUC) of DDS and NAR scores for predicting 3-year DFS were 0.683 and 0.756( P=0.037). In yp0-I stage patients ( n=72), the AUC of DDS and NAR scores for predicting 3-year DFS were 0.762 and 0.569( P=0.032). Conclusions:High DDS and low NAR scores after nCRT indicate good prognosis for patients with LARC. NAR score yields better accuracy than DDS in predicting clinical prognosis, but DDS is significantly better than NAR score in yp0-I stage population.
8.Total neoadjuvant therapy for locally advanced gastric cancer: an interim study of phase Ⅱ clinical trial
Jinming SHI ; Ning LI ; Dongbing ZHAO ; Liming JIANG ; Lin YANG ; Hua REN ; Shulian WANG ; Yongwen SONG ; Yueping LIU ; Hui FANG ; Yong YANG ; Ningning LU ; Yu TANG ; Shunan QI ; Bo CHEN ; Hao JING ; Yexiong LI ; Yuan TANG ; Jing JIN
Chinese Journal of Radiation Oncology 2021;30(10):1025-1029
Objective:To evaluate the safety and preliminary efficacy of total neoadjuvant therapy (TNT) model of" neoadjuvant chemoradiotherapy plus consolidation neoadjuvant chemotherapy (CNCT) followed by surgery" for locally advanced gastric cancer.Methods:From 2018 to 2020, 28 patients clinically diagnosed with locally advanced gastric adenocarcinoma or Siewert Ⅱ/Ⅲ adenocarcinoma gastroesophageal junction cancer were prospectively enrolled. The neoadjuvant chemoradiotherapy (NCRT) was delivered with a total dose of 45 Gy, 1.8 Gy/f. Concurrent chemotherapy was S-1 at a dose of 40-60 mg twice daily. Then, patients received four to six cycles of CNCT of SOX regimen at three weeks after neoadjuvant chemoradiotherapy. D 2 lymphadenectomy was performed at 4-6 weeks after CNCT. Results:A total of 28 patients completed the whole therapy. Grade 3 or above adverse events occurred in 3 cases (11%) during CCRT, including thrombocytopenia, leukopenia and anorexia; 2 cases (7%) developed leukopenia and 3 cases (11%) of thrombocytopenia during CNCT. Twenty patients (71%) completed the surgery. The proportion of patients with pathological complete remission (pCR) was 50%. Three patients experienced surgical complications including anastomotic leak, anastomotic stenosis and intra-abdominal sepsis. All were recovered after symptomatic treatment.Conclusion:Interim analysis results demonstrate that TNT can yield significant down-staging for patients with locally advanced gastric cancer, which causes tolerable adverse events and postoperative complications.
9.Ultrasmall iron oxide nanoparticles inhibit the migration and invasion of human hepatocellular carcinoma HepG2 cells by enhancing autophagy
CHEN Hanren ; JIANG Shulian ; ZHANG Peng ; REN Zhongyu ; CHEN Jianjiao ; WEN Jian
Chinese Journal of Cancer Biotherapy 2021;28(8):783-789
[摘 要] 目的:探讨超微氧化铁纳米粒子(ultrasmall iron oxide nanoparticle,USIONP)对人肝细胞癌HepG2细胞迁移和侵袭的影响及其可能的机制。方法:采用粒径分析仪和透射电镜分别分析USIONP的水合粒径和核心粒径,Zeta电位和胶体稳定性实验分析USIONP的分散性及其稳定性以鉴定USIONP的成功制备;用不同质量浓度USIONP(0、50、100、200 μg/ml)或200 μg/ml USIONP+5 mmol/L 3-MA(自噬抑制剂)联合处理HepG2细胞,CCK-8法检测HepG2细胞的增殖活力,Transwell法检测细胞的迁移和侵袭能力,WB实验检测自噬标志物Beclin1、LC3、p62的表达,2’,7’-二氯二氢荧光素二醋酸(DCFH-DA)法测定细胞内活性氧(ROS)水平,铁离子比色法检测细胞内铁离子水平。结果:USIONP的平均水合粒径为(37.86±12.90) nm、核心粒径约10 nm,Zeta电位为–23.8 mV,有良好的水溶分散性,证实了USIONP的成功制备。随USIONP质量浓度升高和处理时间延长,HepG2细胞的增殖活力明显降低(均P<0.05);与对照组相比,200 μg/ml USIONP处理HepG2细胞24 h后,迁移、侵袭细胞数量均显著减少(均P<0.05),而3-MA能够部分抵消上述影响(均P<0.05)。与对照组相比,100、200 μg/ml USIONP处理组的HepG2细胞中Beclin1和LC3Ⅱ蛋白相对表达水平均显著升高(均P<0.05),而p62蛋白表达水平下降(均P<0.05);200 μg/ml USIONP可显著提高细胞内ROS水平与铁离子水平,而加入3-MA可阻断其作用(均P<0.05)。结论:USIONP能促进HepG2细胞发生自噬,而自噬通路激活后降解USIONP释放铁离子和导致细胞ROS水平升高,从而抑制HepG2细胞的迁移和侵袭。
10.Comparison of outcomes of adult acute lymphoblastic leukemia patients underwent autologous and allogeneic hematopoietic stem cell transplantation.
Yuyan SHEN ; Shulian CHEN ; Donglin YANG ; Yi HE ; Erlie JIANG ; Jialin WEI ; Yong HUANG ; Rongli ZHANG ; Qiaoling MA ; Aiming PANG ; Xin YANG ; Zhao WANG ; Junjie CUI ; Lukun ZHOU ; Xin CHEN ; Sizhou FENG ; Mingzhe HAN
Chinese Journal of Hematology 2015;36(3):210-215
OBJECTIVETo compare the outcomes of adult patients with acute lymphoblastic leukemia (ALL) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSFrom Jan 2007 to Dec 2010, 106 adult ALL patients were retrospectively divided into two groups, 50 in auto-HSCT group and 56 in allo-HSCT group. Auto-HSCT group included 21 patients with high-risk, 46 patients in CR1 and 4 cases in CR2. All the 50 patients had negative minimal residual disease (MRD) prior to HSCT. Allo-HSCT group included 44 patients with high risk, 51 patients in CR1 and 5 cases in CR2, 15 patients with positive MRD before allo-HSCT. response, regulatory T cells (Treg), cytokines levels and treatment-related adverse effects were observed.
RESULTSOf the total 106 patients, 29 patients relapsed at a medium follow-up of 22.9(0.8-63.3) months. The 3-year cumulative relapse rate (RR) was (29.9±8.0) % in auto-HSCT group and (32.7±6.8) % in allo-HSCT group. There were no significant differences in RR and overall survival (OS) between auto-HSCT and allo-HSCT groups, even of stratified risk groups. In standard risk group, 3-year OS was (77.1±13.2) % in auto-HSCT group and (90.9±8.7) % in allo-HSCT group (P=0.739). In high-risk group, 3-year OS was (68.7±10.8) % after auto-HSCT and (45.2±8.5) % after allo-HSCT (P=0.094).
CONCLUSIONDue to acceptable RR and OS, adult ALL patients with no MRD before HSCT showed favorable survival. Auto-HSCT may be a considerable choice for adult ALL patients with negative MRD when lacking of donors for allo-HSCT.
Adult ; Allografts ; Hematopoietic Stem Cell Transplantation ; Humans ; Neoplasm, Residual ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; Recurrence ; Retrospective Studies ; Transplantation, Homologous